Cytisinicline

Smoking cessation

Manufacturer: Achieve Life Sciences
Regulatory submission: NDA resubmission planned for the fourth quarter of 2026
Launch: Anticipated after potential approval in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description

Product information

28 evidence topics · 25 sources

Generic, brand name and therapeutic class of product3 evidence topics · 3 sources
Dosage forms and strengths3 evidence topics · 3 sources
Average sales price and wholesale acquisition cost2 evidence topics · 2 sources
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 1 source
Indication1 evidence topic · 1 source
Pharmacology4 evidence topics · 7 sources
Contraindications/Warnings/Precautions/Adverse effects2 evidence topics · 2 sources
Special populations1 evidence topic · 1 source
Drug/Drug, drug/disease interactions2 evidence topics · 1 source
Dosing and administration3 evidence topics · 3 sources
Access and distribution2 evidence topics · 2 sources
Co-prescribed/Concomitant therapies1 evidence topic · 1 source
Effect of Cytisinicline on quality measures1 evidence topic · 1 source
Product comparison2 evidence topics · 6 sources